DailyMed lists Structured Product Labeling version 10 for the reviewed Abaloparatide label family with a published date of 2021-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 215395 with status AP dated 2021-12-17, and names lanreotide acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 211538 with status AP dated 2021-12-15, and names vasopressin among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 41 for the reviewed Dulaglutide label family with a published date of 2021-12-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 3 for the reviewed Tesamorelin label family with a published date of 2021-12-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 8 for the reviewed Vosoritide label family with a published date of 2021-12-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 215215 with status AP dated 2021-11-26, and names daptomycin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 214938 with status AP dated 2021-11-19, and names vosoritide among the application record's active ingredients.
The Federal Register published notice 2021-25111, attributed to FDA and its parent HHS department, on 2021-11-18. Its official title is “Discovery Therapeutics, LLC, et al.; Withdrawal of Approval of 18 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin and Eptifibatide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209358 with status AP dated 2021-11-10, and names calcitonin salmon among the application record's active ingredients.
The Federal Register published notice 2021-24431, attributed to FDA and its parent HHS department, on 2021-11-09. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Leuprolide.
The Federal Register published notice 2021-24074, attributed to FDA and its parent HHS department, on 2021-11-04. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; SCENESSE,” and PeptideScanner's exact reviewed identity mapping connects the document to Afamelanotide.
DailyMed lists Structured Product Labeling version 40 for the reviewed Dulaglutide label family with a published date of 2021-10-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 39 for the reviewed Dulaglutide label family with a published date of 2021-10-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 4 for the reviewed Afamelanotide label family with a published date of 2021-10-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 9 for the reviewed Abaloparatide label family with a published date of 2021-09-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 28 for the reviewed Linaclotide label family with a published date of 2021-09-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213081 with status AP dated 2021-09-07, and names eptifibatide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213171 with status AP dated 2021-09-02, and names daptomycin among the application record's active ingredients.
The Federal Register published notice 2021-18928, attributed to FDA and its parent HHS department, on 2021-09-02. Its official title is “Proposal To Refuse To Approve a New Drug Application for ITCA 650 (Exenatide in DUROS Device); Opportunity for a Hearing,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 215316 with status AP dated 2021-08-24, and names daptomycin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 214916 with status AP dated 2021-08-23, and names difelikefalin acetate among the application record's active ingredients.
The Federal Register published notice 2021-18072, attributed to FDA and its parent HHS department, on 2021-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Semaglutide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213829 with status AP dated 2021-08-13, and names leuprolide acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 16 for the reviewed Lixisenatide label family with a published date of 2021-08-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2021-16047, attributed to FDA and its parent HHS department, on 2021-07-28. Its official title is “Fresenius Kabi USA, LLC, et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Eptifibatide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213623 with status AP dated 2021-06-29, and names daptomycin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213786 with status AP dated 2021-06-29, and names daptomycin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 210282 with status AP dated 2021-06-21, and names daptomycin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209330 with status AP dated 2021-06-11, and names carfilzomib among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 1 for the reviewed Semaglutide label family with a published date of 2021-06-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 215256 with status AP dated 2021-06-04, and names semaglutide among the application record's active ingredients.
The Federal Register published notice 2021-11575, attributed to FDA and its parent HHS department, on 2021-06-02. Its official title is “Determination That SANDOSTATIN (Octreotide Acetate) Injection, Equal to 0.2 Milligrams Base/Milliliter and Equal to 1 Milligrams Base/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213078 with status AP dated 2021-05-28, and names bivalirudin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213222 with status AP dated 2021-05-21, and names icatibant acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 8 for the reviewed Abaloparatide label family with a published date of 2021-05-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 215014 with status AP dated 2021-05-14, and names pegcetacoplan among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 212416 with status AP dated 2021-05-14, and names calcitonin salmon among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 11 for the reviewed Plecanatide label family with a published date of 2021-04-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 212250 with status AP dated 2021-04-21, and names daptomycin among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 27 for the reviewed Linaclotide label family with a published date of 2021-04-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 38 for the reviewed Dulaglutide label family with a published date of 2021-04-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 26 for the reviewed Linaclotide label family with a published date of 2021-04-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2021-06202, attributed to FDA and its parent HHS department, on 2021-03-25. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Bremelanotide and Octreotide.
The official Drugs@FDA dataset lists original submission 1 for NDA 214231 with status AP dated 2021-03-22, and names dasiglucagon hydrochloride among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 9 for the reviewed Plecanatide label family with a published date of 2021-02-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209564 with status AP dated 2021-02-09, and names linaclotide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 37 for the reviewed Dulaglutide label family with a published date of 2021-01-25. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2021-00118, attributed to FDA and its parent HHS department, on 2021-01-08. Its official title is “Determination That ARALEN (Chloroquine Phosphate) Oral Tablets, 500 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide.